Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research
Completed Award

Dr. Randall Bateman

Randall Bateman, M.D.

Washington University
St. Louis, MO

Title: Human CNS-Apolipoprotein E Isoform Production and Clearance
Non-Technical Title: Metabolism of the protein (ApoE) that increases risk of Alzheimer's Disease in humans.

Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
Award Amount: $150,000

Summary:

Although ApoE is the strongest genetic risk factor for Alzheimer's disease, relatively little is known about the how ApoE contributes to that risk. This study seeks to characterize basic biological differences between three different ApoE alleles.

Details:


Alzheimer's disease is the most common cause of dementia, and the most feared disease of Americans over the age of 65. ApoE is the strongest genetic risk factor for Alzheimer's disease, and is a potential target for disease-modifying therapies. The ApoE4 allele, which occurs in 15 percent of the population, increases one's risk of developing Alzheimer's Disease by 3-fold, while two copies of ApoE4 increase this risk by 12-fold. Whereas the E2 allele, occurring in 7 percent of the population, decreases one's risk of developing Alzeimer's disease. The hypothesis being tested is the three ApoE isoforms (E2, E3 and E4) have different rates of synthesis and clearance. We will measure the metabolism of ApoE from the cerebrospinal fluid of young, non-demented participants. This study will provide an important link regarding how ApoE4 may be involved in the pathophysiology of Alzheimer's disease, and may lead to improved therapeutics, which target the major genetic risk factor of Alzheimer's disease, ApoE.

Publications:

Wildsmith KR, Han B, Bateman RJ. Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Anal Biochem. 2009 Dec 1;395(1):116-8. Epub 2009 Aug 3. PubMed Icon Google Scholar Icon

Wildsmith KR, Han B, Bateman RJ. (2009) Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Anal Biochem. 2009 395(1),116-118 PubMed Icon Google Scholar Icon

Wildsmith, K.R., Patterson, B.W., Bateman, R.J. 2010.Using Tandem MS to Elucidate the Metabolism of CNS-derived Apolipoprotein E3 and Apolipoprotein E4 in Young Normal Control Participants. J Am Soc Mass Spectrom 21(5S):ThP140 [PMID:nd][link not available]

Wildsmith, K.R., Sigurdson, W.C., Bateman, R.J. 2009. Using Stable Isotopes and Tandem MS to study the Metabolism of CNS-derived Apolipoprotein E Isoforms. J Am Soc Mass Spectrom 20(5S):MP601 [PMID:nd][link not available]

Wildsmith, K.R., Browning, K.R., Mawuenyega, K.G., Davis, A.E., Townsend, R.R., and Bateman, R.J. (2008) Quantitating CNS-derived Apolipoprotein E Isoforms using Bottom-up Proteomics. J Am Soc [PMID:nd][link not available]